Exclusion Criteria. Patients meeting any of the following exclusion criteria are not to be enrolled in the study. - Patients with undifferentiated, poorly differentiated GEP-NET, Thoracic or unknown primary NET; - Previous therapy for advanced disease > 1 line or > 2 lines if any of these regimens include treatment with somatostatin analogs previously administered for a long period of time (more than 12 months for Octreotide and more than 6 months for Lanreotide) - Any medical adjuvant treatment must have been stopped at least six months before entry into the study; - Prior treatment with cabozantinib; - Prior treatment with any other tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors is permitted. Prior treatment with non-VEGF-targeted angiogenic inhibitors such as Everolimus is permitted; - Patients who stopped Everolimus or tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors treatment less than 4 weeks prior to the start of the study; - Patients with concomitant treatment with Interferon; - Patients previously treated with chemotherapy, loco-regional therapy (e.g., chemoembolization) or interferon with last administration less than 4 weeks prior to the start of the study or with toxicity not resolved to less or equal grade 1 at the start of the study; - PRRT therapy with last administration less than 6 months prior to inclusion in the study or with toxicity not resolved to less or equal grade 1 at the start of the study; - diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri; - history of any one or more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, coronary artery bypass graft surgery, symptomatic peripheral vascular disease, Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA see Appendix II); - prolongation of QT interval: Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances (e.g., hypokaliemia, family history of long QT Syndrome). Corrected QT interval calculated by the Fridericia formula (QTcF) ≤ 500 ms within 28 days before registration should be shown. Only subjects with a baseline QTcF ≤ 500 ms are eligible for the...
